Status:
COMPLETED
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not ...
Eligibility Criteria
Inclusion
- Patients with acute episode (first or relapse), or upon revisit and identified not achieving remission of schizophrenia or schizoaffective disorder (according to remission criteria of schizophrenia)
- Male or female aged between 18 and 65 years
- Patients recruited from both in-patient and out-patient clinics
- Patients who are cooperative, by judgment from investigators, and the use of oral antipsychotic considered adequate
Exclusion
- Pregnancy or lactation
- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
- Known intolerance, lack of response, or contraindication to prescribed atypical antipsychotic, as judged by the investigator
- Administration of a depot antipsychotic injection within one dosing interval (for the depot) before enrolment and patients prescribed with clozapine within 3 months prior to enrolment
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT00809731
Start Date
December 1 2008
End Date
September 1 2010
Last Update
December 9 2010
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Changhua, Taiwan
2
Research Site
Changhua-Lugang, Taiwan
3
Research Site
Chiayi City, Taiwan
4
Research Site
Kaohsiung-Niosong, Taiwan